Edap Tms S.a. (EDAP)
Oxford Ledge is still expanding full research coverage of EDAP. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
EDAP TMS develops and sells ultrasound-based medical devices for prostate cancer and emerging women's health applications, with revenue from equipment and recurring services.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
Annual results
2 years of annual figures for EDAP, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $70.5M | -$29.2M | -$0.78 |
| 2024 | $69.4M | -$20.6M | -$0.55 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for EDAP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open EDAP in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.